Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (NCT07315113) titled 'Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer' on Dec. 18, 2025.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Nuvectis Pharma, Inc.
Condition:
EGFR Mutation Positive Non-small Cell Lung Cancer
EGFR Mutated Non-small Cell Lung Cancer Patients
Intervention:
Drug: NXP900
Recruitment Status: Recruiting
Phase: Phase 1
Date of First Enrollment: December 18, 2025
Target Sample Size: 18
Countries of Recruitment:
United States
To ...